Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C
暂无分享,去创建一个
X. Forns | M. Londoño | S. M. Martínez | Z. Mariño | J. Carrión | F. Torres | S. Lens | R. Gilabert | Á. García-Criado | R. Solà | C. Brú | M. Puigvehí | J. Sánchez-Tapias | I. García‐Juárez
[1] Jean-Michel Pawlotsky,et al. EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.
[2] L. Henry,et al. Systematic review: patient‐reported outcomes in chronic hepatitis C ‐ the impact of liver disease and new treatment regimens , 2015, Alimentary pharmacology & therapeutics.
[3] M. Trauner,et al. Successful anti‐viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C , 2015, Alimentary pharmacology & therapeutics.
[4] Brian L. Pearlman,et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study , 2014, The Lancet.
[5] K. Kotoh,et al. Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes , 2014, Journal of Gastroenterology.
[6] O. Weiland,et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. , 2014, Gastroenterology.
[7] S. Bertrais,et al. Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C , 2014, Hepatology.
[8] S. Bertrais,et al. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver‐prognosis in chronic hepatitis C , 2014, Alimentary pharmacology & therapeutics.
[9] Riina Salupere,et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. , 2014, The New England journal of medicine.
[10] M. Manns,et al. Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters , 2014, Gut.
[11] H. Mo,et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial , 2014, The Lancet.
[12] A. Lok,et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. , 2014, The New England journal of medicine.
[13] T. Berg,et al. Evaluation of liver disease progression in the German hepatitis C virus (1b)‐contaminated anti‐D cohort at 35 years after infection , 2014, Hepatology.
[14] J. Bosch,et al. Non-Invasive Diagnostic and Prognostic Evaluation of Liver Cirrhosis and Portal Hypertension , 2011, Disease markers.
[15] Laurent Castera,et al. Non-invasive evaluation of liver fibrosis using transient elastography. , 2008, Journal of hepatology.
[16] L. Seeff,et al. Natural history of chronic hepatitis C , 2002, Hepatology.
[17] E. Schiff,et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection , 2002, American Journal of Gastroenterology.
[18] Kenneth Koury,et al. For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .
[19] R. Testa,et al. Increased Levels of γGT Suggest the Presence of Bile Duct Lesions in Patients with Chronic Hepatitis C , 2001, Digestive Diseases and Sciences.
[20] P. Bedossa,et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. , 1999, Journal of hepatology.
[21] F. Gordon,et al. AST/ALT Ratio Predicts Cirrhosis in Patients With Chronic Hepatitis C Virus Infection , 1998, American Journal of Gastroenterology.
[22] L. Bolondi,et al. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. , 1997, Journal of hepatology.
[23] P. Bedossa,et al. Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C , 1994 .
[24] J. Pawlotsky,et al. EASL Recommendations on Treatment of Hepatitis C 2015. , 2015, Journal of hepatology.
[25] William M. Lee,et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. , 2010, Gastroenterology.
[26] R. Testa,et al. Increased levels of gammaGT suggest the presence of bile duct lesions in patients with chronic hepatitis C: absence of influence of HCV genotype, HCV-RNA serum levels, and HGV infection on this histological damage. , 2001, Digestive diseases and sciences.